Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ZL-85FA
- Development stage
- Phase 2
- Lead developer
- Zenitar
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ZL-85FA is a small molecule PARP1 (Poly (ADP-Ribose) polymerase 1) inhibitor currently being developed by Chengdu Zenitar Biomedical Technology. The drug is designed to treat advanced solid tumors by targeting the DNA repair enzyme PARP1, which induces synthetic lethality in cancer cells, particularly those with homologous recombination deficiencies such as BRCA mutations. ZL-85FA is administered orally and is undergoing Phase I/IIa clinical evaluation to assess its safety, tolerability, and preliminary efficacy in patients with various malignancies, including breast, ovarian, fallopian tube, primary peritoneal, and prostate cancers. By selectively inhibiting PARP1, the drug aims to provide a targeted therapeutic option with potentially improved safety profiles compared to first-generation PARP inhibitors.
- Other names
- ZL-85FA tabletsZL85FA tabletsZL 85FA tablets
02
Targets
PARP1 (Poly (adp-ribose) polymerase 1)
Beyond the preview
Go deeper on ZL-85FA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ZL-85FA.